NPS Pharmaceuticals to Present at Needham Healthcare Conference
BEDMINSTER, N.J. -- April 22, 2013
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) will present at the 12^th Annual
Needham Healthcare Conference in New York on Tuesday, April 30, 2013 at 12:50
p.m. ET. The presentation will be available as a live webcast with a replay
available approximately three hours after the presentation has concluded.
Interested parties may access the webcast from the investors’ calendar of
events page on the NPS website at http://www.npsp.com/calendar.
About NPS Pharmaceuticals
NPS Pharmaceuticals is a biopharmaceutical company pioneering and delivering
therapies that transform the lives of patients with rare diseases worldwide.
The company’s lead product, Gattex® (U.S.)/Revestive® (EU) 0.05 mg/kg/d
(teduglutide [rDNA origin]) for injection is approved for adult short bowel
syndrome (SBS). NPS is also developing Natpara® (rhPTH[1-84]) for the
treatment of adult hypoparathyroidism and, subject to the resolution of
certain manufacturing issues, expects to submit its Biologic License
Application (BLA) to the FDA in 2013. NPS's earlier stage pipeline includes
two calcilytic compounds, NPSP790 and NPSP795, with potential application in
rare disorders involving increased calcium receptor activity, such as
autosomal dominant hypocalcemia with hypercalciuria (ADHH). NPS complements
its proprietary programs with a royalty-based portfolio of products and
product candidates that includes agreements with Amgen, GlaxoSmithKline,
Janssen Pharmaceuticals and Kyowa Hakko Kirin.
NPS Pharmaceuticals, Inc.
Gail Brophy, 908-450-5335
Press spacebar to pause and continue. Press esc to stop.